Business
aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial Programs
Company to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDT SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
About this update from Atyr Pharma, Inc.
[{"type":"text","content":"Company to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDT \nSAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced second quarter results and provided a corporate update.\n “While the advent of the global COVID-19 pandemic impacted our Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis, hindering patient enrollment during the second quarter, I am pleased that the majority of our sites are now continuing enrollment. Due to the strong scientific rationale of ATYR1923’s mechanism of action and its overlap with COVID-19 disease pathology, including inflammatory lung injury, during the second quarter we also initiated a Phase 2 trial of ATYR1923 in COVID-19 patients with severe respiratory complications,” said Dr. Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “Additionally, we continue to drive value and build momentum with our pipeline. The preclinical data resulting from our Neuropilin-2 (NRP2) antibody program in oncology demonstrates tumor inhibitory effects and we expect to declare an Investigational New Drug (IND) candidate later this year. We also expect to complete the first phase of our tRNA synthetase research collaboration with CSL Behring early in the fourth quarter.” Second Quarter 2020 and Subsequent Period Highlights Progressed our ongoing Phase 1b/2a clinical trial of ATYR1923 in patients with pulmonary sarcoidosis. The majority of sites have now resumed clinical trial activities and we continue to work with each site to ensure the completion of the trial.Initiated enrollment of a Phase 2 randomized, double blind, placebo-controlled study of ATYR1923 in COVID-19 patients with severe respiratory complications. An independent data and safety monitoring board conducted a pre-planned, blinded interim safety analysis of the initial five patients dosed, which resulted in a positive outcome recommending the trial continue unmodified. Enrollment is ongoing and we expect to report data from this study in the fourth quarter.Published two abstracts in the American Journal of Respiratory and Critical Care Medicine that were also presented as posters at the 2020 American Thoracic Soci...